Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients

This study is exploring whether the mix of bacteria living in your gut (your microbiome) can predict which lung cancer patients will have serious side effects from a drug called durvalumab — an immunotherapy given after chemotherapy and radiation for non-small cell lung cancer (NSCLC). **You may be eligible if...** - You are 18 or older - You have non-small cell lung cancer treated with at least two cycles of platinum-based chemotherapy plus radiation (54–66 Gy) - You have a life expectancy of at least 12 weeks - You are in good physical condition (ECOG 0 or 1) - You are able to follow study visits and procedures **You may NOT be eligible if...** - You have not had the required prior chemotherapy and radiation - Your overall health does not meet the study's organ function requirements - You are unable or unwilling to consent and comply with the study Talk to your doctor to see if this trial is right for you.